The effect of regular exercise and regular exercise with teneligliptin on plasma GLP-1 concetration in the elderly patients with type 2 diabetes

Not Applicable

• Conditions: type 2 diabetes

• Registration Number: JPRN-UMIN000012197
• Lead Sponsor: Geriatric Medicine, Osaka University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) the patients wiht type 1 diabetes 2) the subjects whose HbA1cs are below 6.0% or over 8.0% 3) the subjects who cannot reduce the dosage of sulfonylureas (using more than 2mg/day of glimepiride, 1.25mg/day of glibenclamide, 40mg of gliclazide 4) the subjects with poorly-controlled hypertension (systolic blood pressure >160mmHg) 5) the subjects with a diagonosis of effort angina, chronic heart failure(class II of NHYA classification and more) and tachyarrhythmia 6) the subjects with a diagnosis of chronic respiratory failure(class II of Hugh-Jones classification and more) 7) the subjects who cannot pedal a bike for about 30min 8) the subjects with shorter time of one leg standing (<15sec) 9) the subjects in active treatment for hypothyroidism 10) the subjects with severe liver dysfunction: more than 100IU/L of AST and ALT level 11) the subjects already enrolled in other clinical trial 12) the subjects found offensive by attending physicians for this research

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) The changes in plasma IL-6 or GLP-1 concentration after training in the subjects with or without regular exercise 2) The changes in plasma IL-6 or GLP-1 concentration at rest in the subjects treated with or without teneligliptin, and the enchancing effect on the changes in plasma IL-6 or GLP-1 concentration by the treatment of teneligliptin

Secondary Outcome Measures

Name	Time	Method
The change in 1) fasting blood glucose, HbA1c 2) BMI 3) serum creatinine level 4) plasma IL-6 concentration 5) plasma active GLP-1 concentration 6) intima media thickness (IMT) by carotid ultrasonography